An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine
NCT03934086 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2023-02-23
Summary
The purpose of this protocol is to allow subjects who completed any BHV3000 (rimegepant) clinical study to continue to have access to rimegepant while collecting ongoing safety data.
(NOTE: ONLY FOR PATIENTS who participated in a previous BHV-3000/Rimegepant Clinical Trial in the past)
Conditions
Interventions
- DRUG
-
rimegepant
rimegepant 75 mg
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
NCT04574362 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
NCT05509400 ·Status: COMPLETED ·Phase: PHASE4
-
Randomized Trial in Adult Participants With Acute Migraines
NCT04571060 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
NCT04408794 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants
NCT05371652 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
NCT05207865 ·Status: COMPLETED ·Phase: PHASE4
-
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141 ·Status: RECRUITING ·Phase: PHASE3
-
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242 ·Status: RECRUITING ·Phase: PHASE3
-
Acute Treatment Trial in Adult Subjects With Migraines
NCT03872453 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
NCT04804033 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Trial for Treatment Refractory Trigeminal Neuralgia
NCT03941834 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
NCT05217927 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
NCT05518123 ·Status: COMPLETED ·Phase: PHASE4
-
A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.
NCT06467370 ·Status: COMPLETED
-
Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
NCT01430442 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466 ·Status: RECRUITING ·Phase: PHASE3
-
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04686136 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194 ·Status: RECRUITING ·Phase: PHASE3
-
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
NCT06409832 ·Status: RECRUITING
-
A Prospective Real World Study of Rimegepant in the Treatment of Migraine
NCT05709106 ·Status: COMPLETED
-
Phase 3 Study of MAP0004 in Adult Migraineurs
NCT00623636 ·Status: COMPLETED ·Phase: PHASE3
-
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
NCT06412965 ·Status: COMPLETED
-
A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.
NCT06532357 ·Status: COMPLETED
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398 ·Status: RECRUITING ·Phase: PHASE3
-
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
NCT03939312 ·Status: COMPLETED ·Phase: PHASE3